

William Arcese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/333661/publications.pdf>

Version: 2024-02-01

208
papers

14,241
citations

41344

49
h-index

20358

116
g-index

209
all docs

209
docs citations

209
times ranked

8131
citing authors

#	ARTICLE	IF	CITATIONS
1	Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]. Blood, 1995, 86, 2041-2050.	1.4	1,911
2	Outcome of Cord-Blood Transplantation from Related and Unrelated Donors. New England Journal of Medicine, 1997, 337, 373-381.	27.0	1,255
3	Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia. New England Journal of Medicine, 2004, 351, 2276-2285.	27.0	1,058
4	Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood, 2001, 97, 2962-2971.	1.4	720
5	Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet, The, 1998, 352, 1087-1092.	13.7	609
6	Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncology, The, 2010, 11, 653-660.	10.7	532
7	Factors associated with outcomes of unrelated cord blood transplant: Guidelines for donor choice. Experimental Hematology, 2004, 32, 397-407.	0.4	384
8	Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood, 2012, 119, 332-341.	1.4	246
9	Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood, 2000, 95, 1931-1934.	1.4	243
10	Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood, 2014, 123, 133-140.	1.4	239
11	Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood, 1999, 93, 3662-71.	1.4	230
12	Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet, The, 1992, 340, 1437-1438.	13.7	214
13	Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood, 2013, 121, 849-857.	1.4	209
14	Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia, 2015, 29, 1891-1900.	7.2	199
15	Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and S��ary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2010, 28, 4492-4499.	1.6	191
16	Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood, 2002, 100, 397-405.	1.4	186
17	Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. British Journal of Haematology, 1988, 69, 239-245.	2.5	183
18	Treatment With Granulocyte Colony-Stimulating Factor After Allogeneic Bone Marrow Transplantation for Acute Leukemia Increases the Risk of Graft-Versus-Host Disease and Death: A Study From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2004, 22, 416-423.	1.6	173

#	ARTICLE	IF	CITATIONS
19	Toward Optimization of Postremission Therapy for Residual Disease—Positive Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 4944-4951.	1.6	165
20	Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. <i>Blood</i> , 2003, 102, 4290-4297.	1.4	160
21	Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. <i>Blood</i> , 2006, 107, 4177-4181.	1.4	158
22	Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 1991, 9, 1210-1214.	1.6	152
23	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2019, 134, 935-945.	1.4	148
24	Histone Deacetylase Inhibitor Valproic Acid Enhances the Cytokine-Induced Expansion of Human Hematopoietic Stem Cells. <i>Cancer Research</i> , 2005, 65, 1505-1513.	0.9	147
25	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 872-880.	2.0	141
26	Transplantation of Peripheral Blood Stem Cells as Compared With Bone Marrow From HLA-Identical Siblings in Adult Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 4655-4664.	1.6	136
27	Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 1997, 20, 553-560.	2.4	134
28	A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. <i>British Journal of Haematology</i> , 1996, 93, 637-646.	2.5	133
29	High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenström Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 2227-2232.	1.6	131
30	Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. <i>Blood</i> , 2010, 116, 2295-2303.	1.4	126
31	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. <i>Clinical Infectious Diseases</i> , 2017, 65, 1884-1896.	5.8	103
32	Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group. <i>Blood</i> , 1993, 82, 3211-3219.	1.4	99
33	Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. <i>Lancet</i> , The, 2000, 355, 1393-1398.	13.7	99
34	Stem cell transplantation for chronic myeloid leukemia in children. <i>Blood</i> , 2003, 102, 1224-1231.	1.4	99
35	Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. <i>Leukemia</i> , 2014, 28, 779-786.	7.2	95
36	Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 1993, 12, 509-16.	2.4	92

#	ARTICLE	IF	CITATIONS
37	Onychomycosis As a Possible Origin of Disseminated <i>Fusarium solani</i> Infection in a Patient with Severe Aplastic Anemia. <i>Clinical Infectious Diseases</i> , 1992, 14, 1167-1167.	5.8	88
38	Long-Term Outcome of Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and S��zary Syndrome: A European Society for Blood and Marrow Transplantation Lymphoma Working Party Extended Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3347-3348.	1.6	85
39	Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 47-51.	2.4	84
40	Unrelated cord blood transplants in adults with hematologic malignancies. <i>Haematologica</i> , 2006, 91, 223-30.	3.5	83
41	Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. <i>Lancet</i> , The, 2001, 357, 43-44.	13.7	72
42	Bone Marrow Transplantation in Severe Aplastic Anaemia: a Survey of the European Group for Bone Marrow Transplantation (E.G.B.M.T.). <i>British Journal of Haematology</i> , 1981, 49, 165-173.	2.5	69
43	Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation��a position paper. <i>Clinical Microbiology and Infection</i> , 2017, 23, 935-940.	6.0	69
44	Relevance of Bone Marrow Cell Dose on Allogeneic Transplantation Outcomes for Patients With Acute Myeloid Leukemia in First Complete Remission: Results of a European Survey. <i>Journal of Clinical Oncology</i> , 2002, 20, 4324-4330.	1.6	65
45	Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , 2003, 31, 295-300.	2.4	65
46	A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. <i>Leukemia</i> , 2015, 29, 1069-1075.	7.2	57
47	CLINICAL AND METABOLIC EFFECTS OF DIFFERENT PARENTERAL NUTRITION REGIMENS IN PATIENTS UNDERGOING ALLOGENEIC BONE MARROW TRANSPLANTATION1. <i>Transplantation</i> , 1998, 66, 610-616.	1.0	56
48	Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2007, 39, 461-469.	2.4	55
49	The Surgical Choice in Neutropenic Patients with Hematological Disorders and Acute Abdominal Complications. <i>Leukemia and Lymphoma</i> , 1993, 9, 237-241.	1.3	52
50	Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. <i>Blood</i> , 2003, 102, 3043-3051.	1.4	52
51	HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. <i>Leukemia</i> , 2007, 21, 129-135.	7.2	50
52	Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen. <i>Haematologica</i> , 2014, 99, 1509-1515.	3.5	48
53	Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP*experience. <i>British Journal of Haematology</i> , 1994, 86, 55-61.	2.5	45
54	The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. <i>Blood Advances</i> , 2017, 1, 669-680.	5.2	43

#	ARTICLE	IF	CITATIONS
55	Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2016, 9, 79.	17.0	42
56	Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. <i>Leukemia</i> , 2003, 17, 1930-1933.	7.2	41
57	Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. <i>Journal of Hematology and Oncology</i> , 2018, 11, 110.	17.0	41
58	Excretion of the novel polyomaviruses KI and WU in the stool of patients with hematological disorders. <i>Journal of Medical Virology</i> , 2009, 81, 1668-1673.	5.0	40
59	Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. <i>Seminars in Hematology</i> , 2018, 55, 209-214.	3.4	39
60	High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome Transplant Network. <i>Transplant Infectious Disease</i> , 2014, 16, 158-164.	1.7	38
61	Platelet-rich plasma as treatment for persistent ocular epithelial defects. <i>Transfusion and Apheresis Science</i> , 2015, 52, 300-304.	1.0	38
62	Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukaemia in first remission. <i>British Journal of Haematology</i> , 1997, 96, 387-394.	2.5	37
63	Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literature. <i>Annals of Hematology</i> , 2003, 82, 189-192.	1.8	37
64	The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. <i>Leukemia</i> , 2013, 27, 2086-2091.	7.2	37
65	ABO-incompatible bone marrow transplantation: a GITMO survey of current practice in Italy and comparison with the literature. <i>Bone Marrow Transplantation</i> , 2004, 34, 321-329.	2.4	35
66	Fibrin Glue Therapy for Severe Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1612-1617.	2.0	35
67	Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update. <i>Bone Marrow Transplantation</i> , 2015, 50, S24-S30.	2.4	35
68	High levels of antiphospholipid antibodies are associated with cytomegalovirus infection in unrelated bone marrow and cord blood allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2000, 108, 126-131.	2.5	34
69	Pre-transplant prognostic factors for patients with high-risk leukemia undergoing an unrelated cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2004, 33, 1097-1105.	2.4	33
70	Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2014, 49, 1170-1175.	2.4	33
71	Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R87 protocol. <i>British Journal of Haematology</i> , 1997, 97, 896-903.	2.5	32
72	Gastrointestinal Emergencies in Patients with Acute Intestinal Graft-Versus-Host Disease. <i>Leukemia and Lymphoma</i> , 1998, 29, 129-137.	1.3	32

#	ARTICLE	IF	CITATIONS
73	Autologous stem cell transplantation for adult acute myelocytic leukemia in first remissionâ€”Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Cancer</i> , 2017, 123, 824-831.	4.1	32
74	Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2014, 99, 1380-1386.	3.5	31
75	Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis. <i>Bone Marrow Transplantation</i> , 2014, 49, 24-29.	2.4	31
76	Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1997, 19, 703-707.	2.4	30
77	ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse. <i>British Journal of Haematology</i> , 1997, 99, 671-677.	2.5	30
78	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 6478-6486.	7.0	28
79	Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2018, 93, 859-866.	4.1	28
80	Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. <i>Bone Marrow Transplantation</i> , 2017, 52, 154-156.	2.4	27
81	Impact of marrow unrelated donor search duration on outcome of children with acute lymphoblastic leukemia in second remission. <i>Bone Marrow Transplantation</i> , 2003, 32, 325-331.	2.4	26
82	Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1990, 5, 309-15.	2.4	26
83	Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. <i>Clinical Microbiology and Infection</i> , 2016, 22, 946.e1-946.e8.	6.0	25
84	Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. <i>American Journal of Hematology</i> , 2019, 94, 1091-1097.	4.1	25
85	Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. <i>Leukemia</i> , 2020, 34, 87-99.	7.2	25
86	Fibrin glue for refractory hemorrhagic cystitis after unrelated marrow, cord blood, and haploidentical hematopoietic stem cell transplantation. <i>Transfusion</i> , 2009, 49, 170-175.	1.6	24
87	Monitoring of minimal residual disease in acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2009, 21, 582-588.	2.4	24
88	Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1387-1392.	2.0	24
89	Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a CITMO survey on 809 patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2017, 52, 163-166.	2.4	24
90	Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and S��zary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1391-1401.	2.4	24

#	ARTICLE	IF	CITATIONS
91	Platelet gel for treatment of mucocutaneous lesions related to graft-versus-host disease after allogeneic hematopoietic stem cell transplant. <i>Transfusion</i> , 2010, 50, 501-506.	1.6	23
92	Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 887-894.	2.4	23
93	CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF. <i>Transfusion</i> , 2001, 41, 190-195.	1.6	22
94	Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era. <i>Haematologica</i> , 2012, 97, 1731-1735.	3.5	22
95	Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 68.	17.0	22
96	Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group. <i>Blood</i> , 1993, 82, 3211-3219.	1.4	22
97	Flt3L induces the ex-vivo amplification of umbilical cord blood committed progenitors and early stem cells in short-term cultures. <i>British Journal of Haematology</i> , 1999, 106, 133-141.	2.5	21
98	Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2017, 52, 473-475.	2.4	21
99	Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2018, 11, 307-313.	2.2	21
100	Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1211-1219.	4.1	20
101	Quality assessment of cord blood units selected for unrelated transplantation: A Transplant Center perspective. <i>Transfusion and Apheresis Science</i> , 2010, 42, 289-297.	1.0	19
102	A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood "high-risk" acute lymphoblastic leukaemia: a study of the AIEOP group. <i>British Journal of Haematology</i> , 2002, 118, 741-747.	2.5	18
103	MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016052.	1.3	18
104	Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 1996, 95, 494-500.	2.5	17
105	A fatal case of invasive fungal sinusitis by <i>Scopulariopsis acremonium</i> in a bone marrow transplant recipient. <i>International Journal of Infectious Diseases</i> , 2009, 13, e488-e492.	3.3	17
106	Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant. <i>Journal of Infection</i> , 2016, 72, 265-268.	3.3	17
107	Transcription of latent and replicative Epstein-Barr-virus genes in bone-marrow and peripheral-blood mononuclear cells of healthy donors. , 1997, 70, 524-529.		16
108	Umbilical cord blood transplant from unrelated HLA-mismatched donors in children with high risk leukemia. <i>Bone Marrow Transplantation</i> , 1999, 23, 549-554.	2.4	16

#	ARTICLE	IF	CITATIONS
109	Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. <i>Leukemia</i> , 2019, 33, 1527-1530.	7.2	16
110	Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1373.	4.1	15
111	Standardâ€•versus highâ€•dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization. <i>Transfusion</i> , 2010, 50, 2432-2446.	1.6	14
112	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. <i>Leukemia</i> , 2012, 26, 1779-1785.	7.2	14
113	The potential role of preâ€•transplant HBcIgG seropositivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: A study from the Rome Transplant Network. <i>American Journal of Hematology</i> , 2012, 87, 213-217.	4.1	14
114	Hemolysis in Rh-negative female recipient after Rh-incompatible bone marrow transplantation for chronic myeloid leukemia. <i>Haematologica</i> , 1986, 71, 46-9.	3.5	14
115	Cytogenetic follow-up after allogeneic bone-marrow transplantation for Ph1-positive chronic myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 1990, 5, 119-27.	2.4	13
116	Clinical use of allogeneic hematopoietic stem cells from sources other than bone marrow. <i>Haematologica</i> , 1998, 83, 159-82.	3.5	13
117	A prospective molecular study of chimaerism in patients with haematological malignancies receiving unrelated cord blood or bone marrow transplants: detection of mixed chimaerism predicts graft failure with or without early autologous reconstitution in cor. <i>British Journal of Haematology</i> , 1999, 104, 770-777.	2.5	12
118	Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis. <i>American Journal of Hematology</i> , 2010, 85, 380-383.	4.1	12
119	Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid Tamibarotene. <i>British Journal of Haematology</i> , 2010, 151, 99-101.	2.5	12
120	Minimal residual disease as biomarker for optimal biologic dosing of <scp>ARA</scp>â€•<scp>C</scp> in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, 125-131.	4.1	12
121	THERAPEUTIC EFFICIENCY OF PLATELET GEL FOR THE TREATMENT OF ORAL ULCERS RELATED TO CHRONIC GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION. <i>ORAL and Implantology</i> , 2017, 10, 398.	0.3	12
122	No advantage for patients who receive splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia: results of a prospective randomized study. <i>Bone Marrow Transplantation</i> , 1992, 10, 147-52.	2.4	12
123	Listeriosis in Recipients of Allogeneic Bone Marrow Transplants from Unrelated Donors. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2000, 19, 711-714.	2.9	11
124	Thrombophilic screening in patients with paroxysmal nocturnal haemoglobinuria: a pilot study. <i>British Journal of Haematology</i> , 2010, 150, 492-494.	2.5	11
125	Thiotepaâ€•based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemiaâ€•A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2017, 92, 18-22.	4.1	11
126	Unrelated cord blood transplant in children with high-risk acute lymphoblastic leukemia: a long-term follow-up. <i>Haematologica</i> , 2007, 92, 1051-1058.	3.5	11

#	ARTICLE	IF	CITATIONS
127	T Repleted Haploidentical Mismatch Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation In Adult Patients With Acute Leukemia In Complete Remission (CR): A pair-Matched Analysis From The Acute Leukemia Working Party Of EBMT. <i>Blood</i> , 2013, 122, 3359-3359.	1.4	11
128	Algorithm for donor selection in 2011. <i>Current Opinion in Hematology</i> , 2011, 18, 401-407.	2.5	10
129	Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant. <i>Supportive Care in Cancer</i> , 2012, 20, 891-892.	2.2	10
130	The Rome Transplant Network model compared to the Italian Bone Marrow Donor Registry activity for unrelated donor search process and transplant efficiency for hematologic malignancy. <i>Transfusion</i> , 2017, 57, 1734-1743.	1.6	10
131	Endoscopic Intravesical Fibrin Glue Application in the Treatment of Refractory Hemorrhagic Radiation Cystitis: A Single Cohort Pilot Study. <i>Journal of Endourology</i> , 2019, 33, 93-98.	2.1	10
132	Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion. <i>Bone Marrow Transplantation</i> , 2009, 43, 347-348.	2.4	9
133	Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies. <i>British Journal of Haematology</i> , 2017, 179, 790-801.	2.5	9
134	Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies. <i>Leukemia</i> , 2000, 14, 2052-2058.	7.2	8
135	Granulocyte-mobilized bone marrow. <i>Current Opinion in Hematology</i> , 2012, 19, 448-453.	2.5	8
136	Monitoring of KI and WU polyomaviruses in hematopoietic stem cell transplant patients. <i>Journal of Medical Virology</i> , 2013, 85, 1122-1124.	5.0	8
137	Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. <i>Supportive Care in Cancer</i> , 2019, 27, 793-803.	2.2	8
138	Thiotepa+busulfan+fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1593-1602.	2.4	8
139	Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT In Adults with Acute Leukemia In Remission. An Eurocord and ALWP Collaboration Study. <i>Blood</i> , 2010, 116, 910-910.	1.4	8
140	Hospital Cluster of HBV Infection: Molecular Evidence of Patient-to-Patient Transmission through Lancing Device. <i>PLoS ONE</i> , 2012, 7, e33122.	2.5	8
141	Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group. <i>Blood</i> , 1993, 82, 3211-9.	1.4	8
142	Myelodysplastic syndromes in childhood: description of seven cases. <i>Annals of Hematology</i> , 1994, 68, 241-245.	1.8	6
143	5 The interferons in haematological malignancies. <i>Best Practice and Research: Clinical Haematology</i> , 1994, 7, 91-113.	1.1	6
144	Management of Advanced Acute Lymphoblastic Leukemia in Children and Adults: Results of the ALL R-87 Protocol. <i>Leukemia and Lymphoma</i> , 1998, 32, 89-95.	1.3	6

#	ARTICLE	IF	CITATIONS
145	Adherence to recommendation for chemotherapy-induced nausea and vomiting prophylaxis: the proposal of a score. Supportive Care in Cancer, 2013, 21, 5-6.	2.2	6
146	Quality-of-Life Monitoring During Hematopoietic Stem Cell Transplantation: Observations and a Suggestion From the Rome Transplant Network Quality of Life Working Party. Journal of Pain and Symptom Management, 2013, 45, e2-e3.	1.2	6
147	Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need. Supportive Care in Cancer, 2015, 23, 2211-2211.	2.2	6
148	Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. Annals of Hematology, 2016, 95, 967-972.	1.8	6
149	Homecare-based motor rehabilitation in musculoskeletal chronic graft versus host disease. Indian Journal of Palliative Care, 2011, 17, 159.	1.0	6
150	Fractionated total body irradiation in allogeneic bone marrow transplantation in leukemia patients: analysis of prognostic factors and results in 136 patients. Radiotherapy and Oncology, 1998, 48, 267-276.	0.6	5
151	Bowel ultrasonography as an aid for diagnosis of intestinal acute graft-versus-host-disease after allogeneic haematopoietic stem cell transplantation. Digestive and Liver Disease, 2013, 45, 899-904.	0.9	5
152	Polyomaviruses shedding in stool of patients with hematological disorders: detection analysis and study of the non-coding control region's genetic variability. Medical Microbiology and Immunology, 2019, 208, 845-854.	4.8	5
153	Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT. Blood, 2012, 120, 1975-1975.	1.4	5
154	Splenic Irradiation before Bone Marrow Transplantation for Chronic Myeloid Leukemia: Update of a Prospective Randomized Study. Leukemia and Lymphoma, 1993, 11, 227-231.	1.3	4
155	The Therapeutic Use of Cord Blood. Cell Preservation Technology, 2006, 4, 161-168.	0.6	4
156	Cord blood transplantation in adults with acute myeloid leukaemia. Best Practice and Research in Clinical Haematology, 2010, 23, 197-206.	1.7	4
157	Pre-transplant manipulation processing of umbilical cord blood units: Efficacy of Rubinstein's thawing technique used in 40 transplantation procedures. Transfusion and Apheresis Science, 2010, 43, 173-178.	1.0	4
158	Concurrent search for unrelated cord and volunteer donor in high-risk acute lymphoblastic leukemia. Annals of Hematology, 2012, 91, 941-948.	1.8	4
159	Influence of Myeloablative Conditioning Regimens on Outcomes after Single Unrelated Cord Blood Transplantation for Adults with Leukemia: An Analysis on Behalf of Eurocord-EBMT-Netcord. Blood, 2008, 112, 155-155.	1.4	4
160	Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. Biomedicines, 2022, 10, 443.	3.2	4
161	Pregnancy and secondary cancer after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1999, 23, 752-752.	2.4	3
162	Does the volume reduction manipulation before cryopreservation influence cord blood cell recovery pretransplant?. Transfusion Medicine, 2007, 17, 208-209.	1.1	3

#	ARTICLE	IF	CITATIONS
163	Matched-Pair Analysis of Transplant from Haploidentical, Unmanipulated Bone Marrow Donor versus HLA Identical Sibling for Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1113-1118.	2.0	3
164	Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation. <i>Cancers</i> , 2021, 13, 1083.	3.7	3
165	IDENTIFICATION OF ORAL RISK FACTORS FOR CHRONIC GRAFT VERSUS HOST DISEASE IN HAEMATOLOGICAL PATIENTS WHO UNDERWENT ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION. <i>ORAL and Implantology</i> , 2017, 10, 390.	0.3	3
166	A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015, 126, 3211-3211.	1.4	3
167	ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol. <i>Blood Advances</i> , 2022, 6, 2510-2516.	5.2	3
168	What Does One do for the CML Patient in Relapse After Allogeneic Bone Marrow Transplantation?. <i>Leukemia and Lymphoma</i> , 1993, 11, 213-219.	1.3	2
169	3-Tesla MR spectroscopy in patients subjected to bone marrow transplantation: clinical correlations. <i>Radiologia Medica</i> , 2013, 118, 101-111.	7.7	2
170	Development of cellulitis caused by <i>Aeromonas hydrophila</i> in allogeneic hematopoietic transplantation: a case report. <i>Bone Marrow Transplantation</i> , 2014, 49, 595-596.	2.4	2
171	Patient-reported outcomes and quality of life assessment: New targets for new targeted therapy?. <i>Cancer</i> , 2016, 122, 1461-1462.	4.1	2
172	Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 161-162.	0.4	2
173	Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1387-1394.	2.0	2
174	Non T-Depleted Bone Marrow Transplantation From Haploidentical Related Donor in Hematological Malignancies.. <i>Blood</i> , 2009, 114, 2291-2291.	1.4	2
175	Allogeneic Hematopoietic Cell Transplantation For Patients With Mycosis Fungoides and Sezary Syndrome: The Experience Of The EBMT Lymphoma Working Party With An Extended Five-Year Follow Up. <i>Blood</i> , 2013, 122, 2094-2094.	1.4	2
176	HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 399-399.	1.4	2
177	A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome. <i>Haematologica</i> , 1997, 82, 19-22.	3.5	2
178	Legionellosis after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2555-2566.	2.4	1
179	Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party. <i>Bone Marrow Transplantation</i> , 2021, 56, 2367-2381.	2.4	1
180	Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1563-1572.	2.4	1

#	ARTICLE	IF	CITATIONS
181	Stem Cell Transplantation Can Provide Durable Disease Control in Blastic Plasmacytoid Dendritic Cell Neoplasia (BPDC): A Retrospective Study From the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2011, 118, 3077-3077.	1.4	1
182	Intravenous Busulfan (IV Bu)-Based Conditioning Regimen Before Allogeneic Stem Cell Transplantation (allo-SCT) for Adults with Acute Lymphoid Leukemia (ALL): A Survey From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2011, 118, 3005-3005.	1.4	1
183	CD34 ⁺ CD38 ⁻ CD11 ⁺ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, , 1-5.	1.3	1
184	Rehabilitation need and referrals in hematopoietic stem cell transplantation: the experience of Quality of Life Working Party of the Rome Transplant Network. <i>Bone Marrow Transplantation</i> , 2016, 51, 638-639.	2.4	0
185	Cerebellar Neurocysticercosis as Long-Term Complication of Allogeneic Haematopoietic Stem Cell Transplantation from Haploidentical Donor. <i>Case Reports in Infectious Diseases</i> , 2019, 2019, 1-4.	0.5	0
186	Prof. Franco Mandelli Leukaemia Visionary. May 12, 1931–July 15, 2018. <i>Leukemia</i> , 2019, 33, 285-286.	7.2	0
187	Standard Versus High Dose Lenograstim in Adults with Hematological Malignancies for Peripheral Blood Progenitor Cell Mobilization: Results of a Retrospective Study on Behalf of Rome Transplant Network.. <i>Blood</i> , 2008, 112, 2302-2302.	1.4	0
188	An Intention-to-Treat Analysis of Rome Transplant Network Policy for Alternative Donor Search in Patients Lacking a HLA Matched Related donor. <i>Blood</i> , 2009, 114, 1195-1195.	1.4	0
189	MRD-Directed Post-Remission Therapy Dramatically Improves Outcome of Adult Patients with High Risk AML by Implementing Allogeneic Transplant Option. <i>Blood</i> , 2010, 116, 2702-2702.	1.4	0
190	Incidence and Risk Factors of Chronic Graft-Versus-Host Disease After Unrelated Cord Blood Transplant In Children and Adults. A Retrospective Study on Behalf of EUROCORD and Late-Effect Working Party of EBMT. <i>Blood</i> , 2010, 116, 219-219.	1.4	0
191	Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Cord Blood Transplantation (CBT). Retrospective Analysis on Behalf of Eurocord and the EBMT Autoimmune Diseases Working Party.. <i>Blood</i> , 2010, 116, 3460-3460.	1.4	0
192	The Presence of An Internal Tandem Duplicate of FLT3 Receptor (ITD) Is An Unfavorable Prognostic Factor on the Outcome of Adult Patients with Acute Myeloid Leukemia (AML) Autografted in First Remission (CR1) Only in the Absence of An NPM1 Mutation,. <i>Blood</i> , 2011, 118, 4139-4139.	1.4	0
193	Is There an Impact of HLA Mismatch Direction on Outcomes After Umbilical Cord Blood Transplantation?. <i>Blood</i> , 2011, 118, 835-835.	1.4	0
194	Unrelated Cord Blood Transplantation Using Myeloablative Conditioning Regimen for Adults with Acute Myeloid Leukemia in First Complete Remission. A Survey by EUROCORD and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2011, 118, 836-836.	1.4	0
195	Haploidentical Mismatched Allogeneic Versus Autologous Hematopoietic STEM CELL Transplantation in Adult Patients with ACUTE Myeloid Leukemia (AML) in First Complete Remission (CR1): A Pair-Matched Analysis From the Acute Leukemia Working Party of EBMT.. <i>Blood</i> , 2012, 120, 3093-3093.	1.4	0
196	Impact of Myeloablative and Reduced Intensity Conditioning On Outcomes After Unrelated Cord Blood Transplantation for Adults with Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2012, 120, 3117-3117.	1.4	0
197	Unmanipulated, G-CSF-Primed Bone Marrow Transplantation From Haploidentical Donor for Patients with High-Risk Acute Myeloid Leukemia.. <i>Blood</i> , 2012, 120, 3122-3122.	1.4	0
198	Validation of the CIBMTR Score in Predicting the Outcome of Hematopoietic Stem-Cell Transplantation in AML Patients Not in Complete Remission At the Time of Conditioning: A Retrospective Analysis On Behalf of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2012, 120, 2005-2005.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party. Blood, 2012, 120, 2033-2033.	1.4	0
200	Unmanipulated Graft Transplantation From Family Haploidentical Donors: A Survey On 183 Adult Patients with Acute Leukemias On Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2012, 120, 1987-1987.	1.4	0
201	Long Telomere Length of White Blood Cells Following Umbilical Cord Blood Transplant (UCBT): Is Hematopoiesis Younger in UCBT Recipients Compared to Healthy Age-Matched Controls?. Blood, 2012, 120, 4094-4094.	1.4	0
202	Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission?.. Blood, 2012, 120, 3083-3083.	1.4	0
203	Comparative Efficacy Analysis of Busulfan Dose Intensity Between Two Reduced Intensity Conditioning Regimens (FB2 vs. FB4) for Allogeneic HCT for AML in First Complete Remission: A Report From the EBMT Acute Leukemia Working Party. Blood, 2012, 120, 4153-4153.	1.4	0
204	Unmanipulated Graft Haploidentical Allogeneic Stem Cell Transplantation (Haplo-SCT) In Acute Leukemia: A Long-Term Follow-Up Survey On Behalf Of The Acute Leukemia Working Party (ALWP) Of The European Group For Blood and Marrow Transplantation (EBMT). Blood, 2013, 122, 2105-2105.	1.4	0
205	Haploidentical, Unmanipulated, G-CSF-Primed Bone Marrow Transplantation For Patients With High-Risk Acute Myeloid Leukemia. Blood, 2013, 122, 3356-3356.	1.4	0
206	Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 4316-4316.	1.4	0
207	Donor Age Determines Outcome in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation. Blood, 2017, 130, 850-850.	1.4	0
208	Italian survey on allogeneic BMT for chronic myeloid leukaemia. Bone Marrow Transplantation, 1989, 4 Suppl 4, 90-1.	2.4	0